LAXDAL O E, EVANS G E, BRAATEN V, ROBERTSON H E
Can Med Assoc J. 1964 Jan 4;90(1):15-9.
A new polyvalent respiratory virus vaccine has been evaluated in a double-blind trial involving infants and children. Five hundred and sixteen healthy infants and children were given either nine-strain polyvalent respiratory virus vaccine or placebo. The vaccine contained four Influenza strains, three Adenovirus strains and two Parainfluenza strains. Serologic studies revealed that persistent protective antibody levels were achieved with only the Asian Influenza component.The children were followed up clinically for a one-year period and each respiratory illness was recorded. No protection appeared to have been conferred by the vaccine, and indeed a significantly greater number of respiratory illnesses occurred among the vaccinated group.
一种新型多价呼吸道病毒疫苗在一项涉及婴幼儿和儿童的双盲试验中进行了评估。516名健康婴幼儿和儿童被给予九价多价呼吸道病毒疫苗或安慰剂。该疫苗包含四种流感毒株、三种腺病毒毒株和两种副流感毒株。血清学研究表明,仅亚洲流感成分就能产生持续的保护性抗体水平。对这些儿童进行了为期一年的临床随访,并记录了每一次呼吸道疾病。疫苗似乎没有提供保护作用,实际上,接种疫苗组出现呼吸道疾病的人数显著更多。